๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Metabolic Dysfunction Associated Steatotic Liver Disease
Clinical trial register · China

Metabolic Dysfunction Associated Steatotic Liver Disease Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 4 Shanghai 4 Nanjing 4 Tianjin 2 Ningbo 2
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing4 Shanghai4 Nanjing4 Tianjin2 Ningbo2
All 18 locations
Target enrolment
to

Metabolic Dysfunction Associated Steatotic Liver Disease trials in China

15 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated With Chronic Hepatitis B
NCT07589400Metabolic Dysfunction-associated Steatotic Liver Disease, Chronic Hepatitis b
DrugACT500
Xiamen Amoytop Biotech Co., Ltd.
Phase 1
24
Beijing, Shanghai, รœrรผmqi, Xiamen
2026-10-30
Not yet open
Metformin-Dapagliflozin Effects on IGF-1 in Male T2DM With MASLD
NCT07778719Type 2 Diabetes, Metabolic Dysfunction-Associated Steatotic Liver Disease
The 95th Hospital of Putian๏ผŒPutian, Fujian, China
Not applicable
84
Putian
2026-10-01
Not yet open
Cardiovascular Risk in T2DM With MAFLD: A Cohort Study
NCT07706010Type 2 Diabetes (T2DM), Metabolic Dysfunction-Associated Steatotic Liver Disease
The Affiliated Hospital of Hangzhou Normal University
Observational
7,000
Hanzhou
2026-07-12
Recruiting
Efficacy and Safety of Rifaximin-ฮฑ in Treating MASLD
NCT07381257Metabolic Dysfunction-Associated Steatotic Liver Disease
Shanghai Changzheng Hospital
Phase EARLY_PHASE1
60
Shanghai
2026-01-15
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease
Eli Lilly and Company
Phase 3
4,500
Beijing, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Guiyang
2025-10-15
Not yet open
Prognostic Model for MASLD Related Cirrhosis
NCT07082751Metabolic Dysfunction Associated Steatotic Liver Disease, Compensated Cirrhosis
Beijing Friendship Hospital
Observational
228
Beijing, Tianjin
2025-08-13
Not yet open
Effect of In-Place Slow Jogging on Metabolic Dysfunction-Associated Steatotic Liver Disease
NCT06994234Metabolic Dysfunction-Associated Steatotic Liver Disease
Shanghai East Hospital
Not applicable
82
Shanghai
2025-06-20
Recruiting
Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population
NCT06984510Type 2 Diabetes Mellitus (T2DM), Metabolic Dysfunction-Associated Steatotic Liver Disease, Biological Age
Ningbo No. 1 Hospital
Observational
2,720
Ningbo
2025-04-01
By invitation
Metabolically Healthy Obesity Increases the Risks of MASLD and Hyperuricemia
NCT07001865Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolically Healthy Obesity, Hyperuricemia
Ningbo No. 1 Hospital
Observational
17,040
Ningbo
2025-04-01
Active, closed
Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus Combined With Metabolic Dysfunction-associated Steatotic Liver Disease
NCT07274644Metabolic Dysfunction-Associated Steatotic Liver Disease, Diabetes Mellitus Type 2
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 4
36
Nanjing
2025-03-29
By invitation
Effects of Different Exercises on Intrahepatic Lipid in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease
NCT06994871Metabolic Dysfunction-Associated Steatotic Liver Disease
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Not applicable
186
Nanjing
2025-03-09
Not yet open
Clinical Classification of MAFLD Based Liver Biopsy
NCT06795646Metabolic Dysfunction Associated Steatotic Liver Disease, Metabolic Dysfunction-associated Steatohepatitis (MASH)
Beijing Friendship Hospital
Observational
2,000
Beijing, Hangzhou, Shanghai, Tianjin
2025-02-08
Not yet open
Henagliflozin on Liver Fibrosis in Patients with MASLD and T2DM
NCT06762223Metabolic Dysfunction-associated Steatotic Liver Disease, Type 2 Diabetes Mellitus
Xiqiao Zhou
Phase 4
190
Nanjing
2024-12-31
Recruiting
Hyperbaric Oxygen Therapy for Metabolic Dysfunction-associated Steatotic Liver Diseases
NCT06619808Metabolic Dysfunction-associated Steatotic Liver Disease, Hepatic Steatosis, Non-alcoholic Fatty Liver Diseases
Jinling Hospital, China
Not applicable
150
Nanjing
2024-07-29
Recruiting
Liver Fat as a Dietary Target of the Chinese Medical Nutrition Therapy (CMNT) Diet for Treating Type 2 Diabetes With Nonalcoholic Fatty Liver Disease (Version 3.0)
NCT07083336Type 2 Diabetes Mellitus, Metabolic Dysfunction-associated Steatotic Liver Disease
State Key Laboratory of Subhealth Intervention Technology
Not applicable
120
Yichang, Changsha
2022-06-05
Rows per page Showing 1–15 of 15
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/condition/metabolic-dysfunction-associated-steatotic-liver-disease

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 15 of those studies listing the condition Metabolic Dysfunction Associated Steatotic Liver Disease.

How many Metabolic Dysfunction Associated Steatotic Liver Disease trials are recruiting in China?

5 of the 15 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 7 have not yet opened recruitment, 1 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Metabolic Dysfunction Associated Steatotic Liver Disease), 15 studies
PhaseStudiesRecruitingShare
Not applicable5233.3%
Observational5133.3%
Phase 42013.3%
Phase 1106.7%
Phase 3116.7%
Phase EARLY_PHASE1116.7%

Most active sponsors

Lead sponsors with the most studies (Metabolic Dysfunction Associated Steatotic Liver Disease)
Lead sponsorStudiesRecruiting
Beijing Friendship Hospital20
Ningbo No. 1 Hospital21
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School20
Eli Lilly and Company11
Jinling Hospital, China11
Shanghai Changzheng Hospital11
Shanghai East Hospital10
State Key Laboratory of Subhealth Intervention Technology11
The 95th Hospital of Putian๏ผŒPutian, Fujian, China10
The Affiliated Hospital of Hangzhou Normal University10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.